In part 6, the conclusion of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the response of patients to the new CGM system.
Joel Goldsmith is the Senior Director of Digital Platforms at Abbott Diabetes Care where he and his team are focused on designing, developing, and commercializing software-based products and services.
Transcript of this video segment:
Steve Freed — Being here, you’ve had a chance to meet a lot of different people. What has been the response from people using the Libre system?
Joel Goldsmith –Yeah, the product theater earlier today I think the response was overwhelming. It was a packed house that focused on Freestyle Libre Pro, which of course is available for use in the U.S. today but also sets the stage for the expected availability of the Freestyle Libre system because they are based on a common hardware and software platform so as far as I can tell that the response was extremely positive.
Steve Freed — For type twos that are not on insulin… Obviously for a person on insulin, it could be life and death certainly in helping to lower their blood sugars, having that kind of information. For type two who’s not on insulin, it’s mostly all about postprandial and nutrition, physical activity but probably 90% nutrition. What kind of benefits have you seen for type 2, the older patient as far as wearing this and having an educator or physician go through their food log and see this is what happens when you ate this, this is what happened to ate that? Are you seeing that take place?
Joel Goldsmith –I’m not sure if we have any published studies yet that specifically focus on that patient segment, but I can say with Freestyle Libre Pro it would designed with the clinician in mind to fit into their existing clinical workflow and to be broadly applicable at their discretion. iI some patients it might make sense to do that procedure type once a year simply to confirm that they’re baseline is still where it should be. In other instances, it might be up to 4 times a year, especially for patients who are experiencing recurring complications and need refinement to their treatment regimen so I think that a broad base of patients that it’s applicable to and each practice, depending on the composition of their patient population .will make those choices because the startup cost is so low for the clinic, it’s a great way for them to experiment with that and then judge for themselves which patient types it makes most sense to use it with.
Steve Freed — Thank you for your time.
Joel Goldsmith — My pleasure.
Steve Freed — I think was very informative and enjoy the rest of your time here.